The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
The team aims to release the new resource sometime next year, with the hope that it will become as widely used as other institute databases.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
Newsweek speaks with the University of California, Berkeley's Jennifer Doudna about gene editing.
A paper that asserted that NgAgo could be used in gene editing has been retracted, according to Retraction Watch.
In Nature this week: CRISPR/Cas9 used to correct a disease-causing mutation in embryos, and more.
Researchers have used the gene-editing tool CRISPR/Cas9 to correct a mutation linked to hypertrophic cardiomyopathy in embryos.
The firm has raised a total of $127 million since it launched in 2016, and plans to use the funds to advance its gene editing technology to the clinic.
Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.
The firm recently released two droplet digital PCR-based assays that can characterize edits generated by CRISPR-Cas9 or other genome editing tools.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.